{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"BRIA-ABC","nct_id":"NCT06072612","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bria-abc-nct06072612. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BRIA-ABC","arms":[{"description":"The Bria-IMT regimen:\n\nDay -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site","label":"Bria-IMT Regimen + CPI","type":"EXPERIMENTAL"},{"description":"TPC consists of eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine or taxanes in accordance with the investigators' and institutional standard of care. The specific details of the selected regimen must include every detail of administration including frequency, sequencing (for multi-agent regimens), duration of infusion or oral administration, planned dose, dose prescribed, dose administered, dose adjustments after initial prescription or start of TPC treatment, and any other change in TPC from its initial election prior to randomization.","label":"Treatment of Physician's Choice","type":"ACTIVE_COMPARATOR"},{"description":"The Bria-IMT regimen:\n\nDay -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site","label":"Bria-IMT Regimen Alone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06","type":"ESTIMATED"},"conditions":["Breast Cancer","Metastatic Breast Cancer","Breast Neoplasm","Breast Cancer Metastatic","End Stage Cancer"],"enrollment":{"count":404,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SV-BR-1-GM","otherNames":["Part of the Bria-IMT regimen"],"type":"BIOLOGICAL"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Interferon infiltration of the inoculation site","otherNames":[],"type":"DRUG"},{"name":"Retifanlimab","otherNames":[],"type":"DRUG"},{"name":"Treatment of Physician's Choice","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"BriaCell Therapeutics Corporation","official_title":"Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"Up to 60 months"}],"references":[],"start_date":{"date":"2023-12-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","url":"https://clinicaltrials.gov/study/NCT06072612"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bria-abc-nct06072612"}